17 Nov, 2020– Can-Fite BioPharma Ltd.
today announced that Dr. Rifaat Safadi, Principal Investigator of the Company’s
Phase II study of Namodenoson in the treatment of NAFLD/NASH delivered a
late-breaking oral presentation at the AASLD conference, The Liver Meeting Digital
Experience? 2020.
Titled “A Phase 2, Randomized,
Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety
Of Namodenoson (CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating
Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic Steatohepatitis
(NASH)” the oral presentation was given on Sunday, November 15 by Dr. Safadi,
Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of
Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver
Disease, and Metabolic Syndrome at Hebrew University in Israel.
The double-blind,
placebo-controlled, dose-finding efficacy and safety study enrolled 60 patients
with NAFLD with or without NASH. Patients with evidence of an active
inflammation were treated twice daily with 12.5 mg (n=21) or 25 mg (n=19) of
oral Namodenoson vs. placebo (n=20). The patients were treated for 12 weeks and
followed-up until week 16. As a result of the study, 25 mg was determined to be
the optimal dose.
“We
were very pleased that the AASLD accepted our late breaking abstract for an
oral presentation, a prominent platform through which we shared these important
study results with the leading scientists and health care professionals
committed to preventing and curing liver diseases. We thank Dr. Safadi for
delivering the presentation,” stated Can-Fite CEO Dr. Pnina Fishman.
Dr. Safadi added,
“Namodenoson’s very impressive study data may result in a promising drug for
the treatment of NAFLD/NASH due to the combination of good efficacy and
favorable safety.”
The original website link: